Pharmacokinetic variability and use of therapeutic drug monitoring of cannabidiol in patients with refractory epilepsy
This observational study with TDM data revealed extensive pharmacokinetic variability of CBD in patients with refractory epilepsy. The results demonstrate the need for close follow-up and use of TDM, including biochemical markers of toxicity, for individualized treatment with CBD.
Authors
- André Gottås (ORCID: https://orcid.org/0000-0002-4311-8434)
- Margrete Larsen Burns (ORCID: https://orcid.org/0000-0001-8121-899X)
- Torleiv Svendsen (ORCID: https://orcid.org/0000-0002-8986-1020)
- Erik Sætre
- Svein I. Johannessen (ORCID: https://orcid.org/0000-0001-7087-6655)
- Elisabeth Leere Øiestad (ORCID: https://orcid.org/0000-0003-0781-6865)
- Tao Angell‐Petersen McQuade
- Anne Karine Våtevik
- Cecilie Johannessen Landmark (ORCID: https://orcid.org/0000-0002-0877-8912)
- Signe Flood Kjeldsen
- Johan Sætre
- Martha Wolden
Institutions
- Oslo University Hospital (NO)
- OsloMet – Oslo Metropolitan University (NO)
- University of Oslo (NO)
- Sandvik (Norway) (NO)
Publication Details
- Journal
- Epilepsia
- Published
- 2025-02-22
- DOI
- https://doi.org/10.1111/epi.18284
- Citations
- 8
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 11.77